ATE294804T1 - Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer - Google Patents

Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer

Info

Publication number
ATE294804T1
ATE294804T1 AT01938263T AT01938263T ATE294804T1 AT E294804 T1 ATE294804 T1 AT E294804T1 AT 01938263 T AT01938263 T AT 01938263T AT 01938263 T AT01938263 T AT 01938263T AT E294804 T1 ATE294804 T1 AT E294804T1
Authority
AT
Austria
Prior art keywords
annellated
farnesyl
pharmaceutical composition
composition containing
transferase inhibiting
Prior art date
Application number
AT01938263T
Other languages
German (de)
English (en)
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE294804T1 publication Critical patent/ATE294804T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01938263T 2000-06-22 2001-06-13 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer ATE294804T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (1)

Publication Number Publication Date
ATE294804T1 true ATE294804T1 (de) 2005-05-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938263T ATE294804T1 (de) 2000-06-22 2001-06-13 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100831940B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU6396201A (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
DK3285768T3 (da) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
HUE057306T2 (hu) 2015-08-17 2022-04-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI1162201T1 (sl) * 1995-12-08 2006-08-31 Janssen Pharmaceutica Nv (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
KR100520401B1 (ko) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
PT1094839E (pt) * 1998-07-06 2003-09-30 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase com propriedades de radiossensibilizacao (in vivo)
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ES2259237T3 (es) * 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
AU4925199A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
EA004542B1 (ru) * 1998-12-23 2004-06-24 Янссен Фармацевтика Н.В. 1, 2-аннелированные производные хинолина
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
AU2124800A (en) * 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
BR0111743A (pt) 2003-07-08
NO20026032L (no) 2002-12-16
CZ2003114A3 (cs) 2003-05-14
AU2006220405A1 (en) 2006-10-12
KR100831940B1 (ko) 2008-05-23
AU2006220405B2 (en) 2009-05-21
UA73572C2 (en) 2005-08-15
CN1437601A (zh) 2003-08-20
HUP0300872A2 (hu) 2003-07-28
EA005065B1 (ru) 2004-10-28
EP1296984A1 (en) 2003-04-02
US8329714B2 (en) 2012-12-11
IL153560A (en) 2011-06-30
NO20026032D0 (no) 2002-12-16
IS2596B (is) 2010-03-15
CN1207296C (zh) 2005-06-22
MXPA02012845A (es) 2003-05-15
AR030704A1 (es) 2003-09-03
PL209521B1 (pl) 2011-09-30
BG65894B1 (bg) 2010-04-30
IS6590A (is) 2002-10-25
SK285699B6 (sk) 2007-06-07
EE04966B1 (et) 2008-02-15
HU229095B1 (en) 2013-07-29
IL153560A0 (en) 2003-07-06
EE200200695A (et) 2004-06-15
SA01220349B1 (ar) 2007-01-23
HRP20020989A2 (en) 2005-02-28
HK1058363A1 (en) 2004-05-14
PL358918A1 (en) 2004-08-23
EA200300048A1 (ru) 2003-04-24
EG24180A (en) 2008-09-28
CA2410232A1 (en) 2001-12-27
DE60110592T2 (de) 2006-01-19
ES2241830T3 (es) 2005-11-01
JP4919575B2 (ja) 2012-04-18
WO2001098302A1 (en) 2001-12-27
SK502003A3 (en) 2003-05-02
BG107310A (bg) 2003-07-31
AU6396201A (en) 2002-01-02
KR20030009463A (ko) 2003-01-29
CA2410232C (en) 2008-10-07
US20070259902A1 (en) 2007-11-08
HRP20020989B1 (hr) 2011-05-31
EP1296984B1 (en) 2005-05-04
US20080114009A1 (en) 2008-05-15
US20030114471A1 (en) 2003-06-19
NO324494B1 (no) 2007-10-29
AU2001263962B2 (en) 2006-07-20
KR100846370B1 (ko) 2008-07-15
ZA200210305B (en) 2004-03-19
CZ295278B6 (cs) 2005-06-15
KR20070121847A (ko) 2007-12-27
BRPI0111743B1 (pt) 2019-03-26
MY127734A (en) 2006-12-29
US8318753B2 (en) 2012-11-27
BRPI0111743B8 (pt) 2021-05-25
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
NZ522481A (en) 2004-09-24
JO2361B1 (en) 2006-12-12
HUP0300872A3 (en) 2004-11-29
PA8519501A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
EG24357A (en) New Pharmaceutical composition
ATE359064T1 (de) Pharmazeutische tramadolsalze
DE60127002D1 (de) Pharmazeutische zusammensetzung
FI991485L (fi) Uusi farmaseuttinen koostumus
DK1251857T3 (da) Paranteralt farmaceutisk præparat indeholdende et biphosphonat
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO20015175L (no) Farmasöytisk sammensetning
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
NO20014926D0 (no) Farmasöytiske forbindelser
ATE366128T1 (de) Pharmazeutische zusammensetzung
FI5176U1 (fi) Sitalopraamia sisältävä farmaseuttinen koostumus
IT1313579B1 (it) Composizione farmaceutica liquida a base di paracetamolo.
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE294804T1 (de) Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
EP1124557A4 (en) Pharmaceutical composition
GB0019272D0 (en) Pharmaceutical compounds
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296984

Country of ref document: EP